Q32 Bio (QTTB) Non-Current Deffered Revenue (2017 - 2022)

Q32 Bio's Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $354000.0 for Q1 2022.

• In Q1 2022, Non-Current Deffered Revenue fell 90.06% year-over-year to $354000.0; the TTM figure through Mar 2022 stood at $354000.0 (down 90.06% YoY), while the FY2021 annual figure was $1.2 million, down 96.4% from the prior year.
• Non-Current Deffered Revenue was $354000.0 for Q1 2022 at Q32 Bio, down from $1.2 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $32.1 million in Q4 2020 to a low of $354000.0 in Q1 2022.
• Historically, Non-Current Deffered Revenue has averaged $19.0 million across 5 years, with a median of $29.7 million in 2018.
• The sharpest annual moves came in 2018 and 2021: Non-Current Deffered Revenue soared 10467.01% in 2018, then sank 96.4% in 2021.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $30.8 million in 2018, then retreated by 1.98% to $30.1 million in 2019, then increased by 6.64% to $32.1 million in 2020, then tumbled by 96.4% to $1.2 million in 2021, then sank by 69.38% to $354000.0 in 2022.
• The last three Non-Current Deffered Revenue figures came in at $354000.0 (Q1 2022), $1.2 million (Q4 2021), and $2.0 million (Q3 2021), per Business Quant data.